Research In Practice:

Prostate Health Index (phi) Reduces Unnecessary Biopsies in the Clinic

Categories: Summer/Fall 2017

Clinical trials found that using the Prostate Health Index (phi) test could have spared 30% of unnecessary biopsies for patients who had benign or insignificant prostate cancer. A new study looked at the impact of phi testing in a real-world clinical setting. When compared to patients who did not have phi tests, the study showed that incorporating phi into clinical practice reduced unnecessary biopsies by 9% while still detecting the same proportion of clinically-significant cancers.

Phi is a simple blood test that is nearly three times more accurate than the free/total PSA test. Dr. Catalona led the pivotal study on phi that gained its approval by the U.S. FDA.

Subscribe to Quest

"*" indicates required fields

Email

This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*
Address*